Floatz logo

Epi-506

Male Reproductive System Disorder

ESSA PharmaceuticalsSmall moleculePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

2 Active assets in the Male Reproductive System Disorder cohort.

Asset / SponsorPhaseRating
STI571
Novartis Pharmaceuticals
Phase 2B
Psma-Hbed-Cc Alf-18
Alessandro D'Agnolo
Phase 2B
Ixabepilone
Cedars-Sinai Medical Center
Phase 2CCC
Darolutamide
Celcuity Inc
Phase 1/2CCC
Gedatolisib
Celcuity Inc
Phase 1/2CC

Same molecule, other indications

Epi-506 is also rated in:

male reproductive system neoplasmDormant
CCC
Indicative · Phase 1/2
48 / 100
View asset →
prostate disorderDormant
CCC
Indicative · Phase 1/2
48 / 100
View asset →
prostate neoplasmDormant
CC
Indicative · Phase 1/2
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →